Literature DB >> 28444577

Comparison of clinical, serological, and prognostic differences among juvenile-, adult-, and late-onset lupus nephritis in Korean patients.

Ji-Hyoun Kang1, Dong-Jin Park1, Kyung-Eun Lee1, Ji Shin Lee2, Yoo-Duk Choi2, Shin-Seok Lee3.   

Abstract

We investigated whether lupus nephritis (LN) patients could be distinguished based on the time of disease onset and, if so, whether the groups differed in their clinical and laboratory features and long-term prognosis in ethnically homogeneous Korean patients. We enrolled 117 systemic lupus erythematosus patients with available clinical data at the time of renal biopsy of LN. Sociodemographic, clinical, and laboratory data and concomitant diseases were evaluated at the time of renal biopsy. We divided LN patients, according to age at LN diagnosis, into three groups: juvenile-onset LN (JLN, diagnosed at ≤18 years), adult-onset LN (ALN, diagnosed at 18-50 years), and late-onset LN (LLN, diagnosed at >50 years) and compared demographic, clinical, histological, and laboratory findings. We also compared treatment and long-term prognosis of LN. Of the 117 LN patients, 20 (17.8%), 84 (71.3%), and 13 (10.9%) were JLN, ALN, and LLN patients, respectively. LLN patients showed higher white blood cell counts and lower estimated glomerular filtration rate than ALN or LLN patients. LLN patients had higher chronicity indices and scores. Anti-Ro antibodies were found more frequently in ALN patients, and lower complement levels were more common in JLN patients. During a mean follow-up of 76.5 months, development of chronic kidney disease and death were higher in LLN patients than in JLN and ALN patients. LLN patients showed higher chronicity indices and deterioration of kidney function and death in long-term follow-up compared with JLN and ALN patients. Therefore, LLN patients should be carefully monitored to avoid poor outcomes.

Entities:  

Keywords:  Age; Lupus nephritis; Onset; Systemic lupus erythematosus

Mesh:

Year:  2017        PMID: 28444577     DOI: 10.1007/s10067-017-3641-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  28 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 3.  Adult outcomes of childhood-onset rheumatic diseases.

Authors:  Aimee Hersh; Emily von Scheven; Ed Yelin
Journal:  Nat Rev Rheumatol       Date:  2011-04-12       Impact factor: 20.543

Review 4.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

5.  Lupus nephritis is more severe in children and adolescents than in older adults.

Authors:  V A H Sato; I D B Marques; P T Goldenstein; L P F Carmo; L B Jorge; S M O Titan; R T Barros; V Woronik
Journal:  Lupus       Date:  2012-03-26       Impact factor: 2.911

6.  Late onset lupus nephritis in Chinese patients: classified by the 2003 International Society of Nephrology and Renal Pathology Society system.

Authors:  Y-X Xu; Y Tan; F Yu; M-H Zhao
Journal:  Lupus       Date:  2011-05-04       Impact factor: 2.911

7.  Comparison of clinical and serological differences among juvenile-, adult-, and late-onset systemic lupus erythematosus in Korean patients.

Authors:  J H Choi; D J Park; J H Kang; Y R Yim; K E Lee; J W Lee; L Wen; T J Kim; Y W Park; J K Lee; S S Lee
Journal:  Lupus       Date:  2015-06-17       Impact factor: 2.911

8.  Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus.

Authors:  X Feng; Y Zou; W Pan; X Wang; M Wu; M Zhang; J Tao; Y Zhang; K Tan; J Li; Z Chen; X Ding; X Qian; Z Da; M Wang; L Sun
Journal:  Lupus       Date:  2013-12-02       Impact factor: 2.911

9.  Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions.

Authors:  N Hiramatsu; T Kuroiwa; H Ikeuchi; A Maeshima; Y Kaneko; K Hiromura; K Ueki; Y Nojima
Journal:  Rheumatology (Oxford)       Date:  2008-04-04       Impact factor: 7.580

Review 10.  Update on differences between childhood-onset and adult-onset systemic lupus erythematosus.

Authors:  Rina Mina; Hermine I Brunner
Journal:  Arthritis Res Ther       Date:  2013-08-21       Impact factor: 5.156

View more
  5 in total

1.  Native kidney biopsies in older adults: disease spectrum, long-term kidney and patient survival and safety.

Authors:  Hui Zhuan Tan; Benson Siow; Jason Chon Jun Choo; Alwin Hwai Liang Loh; Fiona Hui Ing Yeo; Irene Mok; Puay Hoon Tan; Choong Meng Chan; Chieh Suai Tan; Keng Thye Woo; Cynthia Ciwei Lim
Journal:  Int Urol Nephrol       Date:  2022-02-12       Impact factor: 2.266

2.  Spectrum of systemic lupus erythematosus in Oman: from childhood to adulthood.

Authors:  Asma Al Rasbi; Eiman Abdalla; Rabab Sultan; Nasreen Abdullah; Juma Al Kaabi; Ibrahim Al-Zakwani; Reem Abdwani
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

3.  Changing trends in presentation and indications of biopsy in lupus nephritis: data from the Spanish Registry of Glomerulonephritis.

Authors:  Amir Shabaka; Eugenia Landaluce-Triska; José Emilio Sánchez-Álvarez; Gema Fernández-Juárez
Journal:  Clin Kidney J       Date:  2021-11-26

4.  Disease characteristics in patients with juvenile- and adult-onset systemic lupus erythematosus: A multi-center comparative study.

Authors:  Sherif M Gamal; Nermeen Fouad; Nora Yosry; Wael Badr; Nesreen Sobhy
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

Review 5.  Oral Manifestations of Systemic Lupus Erythematosus: A Systematic Review.

Authors:  Paula García-Ríos; María Pilar Pecci-Lloret; Ricardo Elías Oñate-Sánchez
Journal:  Int J Environ Res Public Health       Date:  2022-09-21       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.